Equities Analysts Offer Predictions for ZNTL FY2029 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.08) per share for the year. Wedbush has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.48) per share.

Several other brokerages have also recently commented on ZNTL. Guggenheim reduced their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday. HC Wainwright lowered their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $1.66 on Friday. Zentalis Pharmaceuticals has a one year low of $1.66 and a one year high of $18.07. The firm has a market capitalization of $118.30 million, a P/E ratio of -0.67 and a beta of 1.86. The company’s fifty day moving average is $2.97 and its two-hundred day moving average is $3.29.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. American Century Companies Inc. purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at $95,000. Bank of Montreal Can acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $402,000. Squarepoint Ops LLC lifted its holdings in Zentalis Pharmaceuticals by 543.8% in the 2nd quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock valued at $608,000 after purchasing an additional 125,649 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $78,000. Finally, SG Americas Securities LLC boosted its stake in shares of Zentalis Pharmaceuticals by 84.8% during the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock worth $96,000 after purchasing an additional 11,997 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.